Topics

On second thought, AbbVie's new arthritis drug not so costly, ICER says

08:01 EDT 11 Oct 2019 | BioPharmaDive

A re-evaluation of Rinvoq makes it look like a better value, although the group's estimate says it offers "marginal clinical benefit" when compared to Humira.

Original Article: On second thought, AbbVie's new arthritis drug not so costly, ICER says

NEXT ARTICLE

More From BioPortfolio on "On second thought, AbbVie's new arthritis drug not so costly, ICER says"

Quick Search